Transfusion therapy in paediatric trauma patients: a review of the literature by unknown
Nystrup et al. Scandinavian Journal of Trauma,
Resuscitation and Emergency Medicine  (2015) 23:21 
DOI 10.1186/s13049-015-0097-zREVIEW Open AccessTransfusion therapy in paediatric trauma patients:
a review of the literature
Kristin Brønnum Nystrup1,2*, Jakob Stensballe1,3, Morten Bøttger3, Pär I Johansson1,4 and Sisse R Ostrowski1Abstract
Haemorrhage is a leading cause of death in paediatric trauma patients. Predefined massive transfusion protocols
(MTP) have the potential to significantly reduce mortality by treating haemorrhagic shock and coagulopathy, in
adhering to the principles of haemostatic resuscitation with rapid administration of balanced ratios of packed red
blood cells (RBC), fresh frozen plasma (FFP) and platelets (PLT).
Because of their substantial physiological reserve, initial vital signs may not be good predictors of early
haemorrhage in paediatric patients. Determining the triggers for MTP activation in paediatric trauma patients is
challenging, and the optimal blood product ratio that will increase survival in massively bleeding paediatric trauma
patients has yet to be determined. To date, only a few small descriptive studies and case reports have investigated
the use of predefined MTP in paediatric trauma patients.
MTP with increased FFP or PLT to RBC ratios combined with viscoelastic haemostatic assay (VHA) guided
haemostatic resuscitation have not yet been tested in paediatric populations but based on results from adult
trauma patients, this therapeutic approach seems promising.
Considering the high prevalence of early coagulopathy in paediatric trauma patients, immediate identification and
implementation of VHA-directed treatment of traumatic coagulopathy could ensure faster haemostasis and thereby,
potentially, reduce bleeding as well as the total transfusion requirements and further improve outcome in paediatric
trauma patients. Prospective randomized trials investigating this therapeutic approach in paediatric trauma patients
are highly warranted.
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Globally, injuries account for an estimated 950,000 deaths
annually in children less than 18 years of age and in high-
income countries, injuries cause nearly 40% of all child
deaths [1]. Leading causes of death in paediatric trauma
patients include traumatic brain injury (TBI) and haemor-
rhage [2,3].
Coagulopathy is present in about one third of adult
trauma patients on emergency department (ED) arrival
[4,5]. Traumatic coagulopathy is at least as prevalent in
paediatric trauma patients and is, similar to adults, as-
sociated with increased morbidity and mortality [3,6-8].* Correspondence: kristinnystrup@gmail.com
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unless otherwise stated.Massive transfusion protocols (MTP) are designed to pro-
vide the right amount and balance of blood products, mim-
icking whole blood, to critically injured patients in order to
prevent and treat haemorrhagic shock and coagulopathy
[9,10]. MTPs are based on the recently developed concept
of damage control resuscitation (DCR), which advocates
early blood component therapy together with minimal crys-
talloid use directed towards hypotensive resuscitation whilst
avoiding haemodilution, combined with rapid surgical con-
trol [11,12].
An intricate part of the DCR concept is a balanced
transfusion strategy with packed red blood cells (RBC),
fresh frozen plasma (FFP) and platelets (PLT) in a 1:1:1
unit ratio with the appropriate use of coagulation factors
such as fibrinogen-containing products, prothrombin
complex concentrate and recombinant FVIIa, alternatively
fresh whole blood where available. This transfusion strat-
egy is termed haemostatic resuscitation (HR) [11,12]. Thel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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complications of hypoperfusion, acidosis, hypothermia
and coagulopathy that often accompany substantial
haemorrhage in patients with severe traumatic injuries
[11,13,14].
Early administration of predefined balanced ratios of
RBC, FFP and PLT have been shown to be associated
with improvements in patient outcome in adult trauma
and non-trauma patients [15-18], though the optimal ra-
tio of PLT and FFP to RBC is currently being investi-
gated in a randomized controlled trial [19]. As in adults,
the optimal ratio for blood product administration in
paediatric trauma patients in need of massive transfusion
is unknown [20-22]. There is an urgent need for evi-
dence based guidelines on massive transfusion therapy
for this population [23,24]. The purpose of this review is
to summarise the current evidence regarding transfusion
therapy in massively bleeding paediatric trauma patients.
Special considerations in the paediatric trauma patient
Massive bleeding has historically been defined as the loss
of one or more circulating blood volumes and in paedi-
atric patients, all estimates of blood volume, volume loss
and volume replacement are based on weight with chil-
dren over the age of 3 months having an estimated
blood volume of 70 ml/kg, and younger infants having
an estimated 90 ml/kg [23-25].
The clinical signs and symptoms of hypovolaemia in
children may vary from adults because of their substantial
physiological reserve, and initial vital signs may not be
good predictors of early haemorrhage. Children are able to
maintain a normal blood pressure until a loss of more
than 20% of their blood volume [2,20,25]. A narrow pulse
pressure may be a more sensitive sign of hypovolaemia
than tachycardia or systolic hypotension, and metabolic
acidosis secondary to hypoperfusion and decreased urine
output are additional indicators of hypovolaemia [25]. Like
adults, large amounts of blood may be lost internally sec-
ondary to long bone fractures, retroperitoneal or abdom-
inal trauma and, unique to children, substantial bleeding
may occur due to closed head trauma [25].
Clinical monitoring should focus on perceived tissue
oxygenation with continuous measurements of heart rate,
pulse oximetry, arterial blood pressure and in massively
bleeding patients, invasive monitoring should include re-
peated measurements of lactate and mixed venous oxygen
saturation [21]. Children are at least as capable as adults
in their ability to compensate for lower haemoglobin con-
centrations with increased oxygen extraction and cardiac
output [26], despite their limited myocardial compliance
[21]. However, compared to adults, children have in-
creased energy requirements resulting in higher tissue
oxygen utilization [21], and a transient increase in brain
tissue oxygen tension after RBC transfusion has beenfound [27], emphasizing the utility of RBC for increasing
oxygen delivery to hypoxic tissues. In this study, the
majority (70%) of the transfused RBC had been
stored ≤ 14 days.
A specific level of blood loss or anaemia that triggers
RBC transfusion has not yet been defined in paediatric pa-
tients [23,24]. A study done on haemodynamically stable,
critically ill paediatric patients, the TRIPICU trial, showed
no adverse effects when comparing a restrictive transfu-
sion strategy initiated at a haemoglobin level of 7 g/dl to a
transfusion threshold of 9.5 g/dl [28]. A specific anaemia
threshold would be difficult to use as a trigger for MTP
activation in the case of massive haemorrhage, because
haemoglobin and haematocrit levels might not reveal sig-
nificant anaemia until the patient had been volume resus-
citated, making a precise estimate of lost blood volume
difficult to ascertain based on these laboratory tests
[23,25].
The paediatric haemostatic system – mature from
6 months of age
The haemostatic system is incompletely developed at birth
and matures throughout infancy. Both full-term and pre-
term neonates are born with low levels of most procoagu-
lant proteins including all the contact activation factors and
vitamin K-dependent factors [29]. Similarly, levels of the
major anticoagulant proteins (tissue factor pathway inhibi-
tor, antithrombin, protein C) are low at birth. The concen-
trations of these proteins remain low compared to adults
until approximately 6 months of age [29-31]. Neonatal plate-
let counts do not differ from that in adults, but neonatal fi-
brinogen is qualitatively dysfunctional existing in a foetal
form until approximately 6 months to 1 year of age. Further-
more, plasminogen is both quantitatively and qualitatively
different from that in adults until 6 months of age. This
leads to reduced plasmin generation and fibrinolytic activity
of infants [29]. The differences compared to adults are pri-
marily quantitative [30], ensuring that neonates and infants
have an overall balanced and efficient haemostasis, unless
disrupted by critical illness [29]. Due to the reduced concen-
tration of procoagulant proteins, it might be assumed that
young infants are at higher risk of bleeding than adults,
since this will prolong the prothrombin time (PT) and acti-
vated partial thromboplastin time (APTT). Relying on trans-
fusion thresholds based on these standard plasma based
coagulation tests could, however, lead to over transfusion of
blood products such as FFP [32,33]. Functional viscoelastic
assays analyzing whole blood may provide more accurate in-
formation since they evaluate the entire haemostatic process
[34], as described later.
Physiological predictors of adverse outcome
A high Injury Severity Score (ISS), shock [7,35] and high
base deficit [7,36] on admission are all independent
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ric trauma population.
Severe TBI is the leading cause of death in children over
the age of 1 year, and since hypoxia and hypotension are
major causes of secondary brain lesions that worsen out-
come, initial resuscitation efforts should aim at minimizing
the extent and duration of these conditions [35]. Several
investigators have confirmed that low Glasgow Coma Scale
(GCS) score on admission is an independent predictor of
mortality in paediatric patients with TBI [7,22,35].
Patregnani et al. found that coagulopathy (international
normalized ratio (INR) ≥ 1,5) on admission was common
and associated with increased mortality in children with
traumatic injuries, independent of the ISS [7]. The same
association was shown by other investigators, who also
found that the incidence of coagulopathy in paediatric
trauma patients increased with higher ISS and in patients
with TBI [6,37,38]. Vavilala et al. found that the presence
of coagulopathy (defined by increased fibrin degradation
products) independently predicted poor outcome in chil-
dren with isolated head injury [39]. Several mechanisms
have been proposed to explain the coagulation abnormal-
ities associated with TBI, which show a combination of
both hypocoagulable and hypercoagulable states [40]. It
has also been hypothesized that the trauma causes local
release of tissue factor from the injured neurons, which is
associated with activation of the protein C pathway, thus
triggering the release of anticoagulant mediators [34,41].
Borgman et al. found both admission base deficit < 8
and INR > 1.8 to be independently associated with mor-
tality, and proposed that a score based on these predic-
tors of adverse outcome (“BIG” score: base deficit + [2.5
× INR] + [15 – GCS score]) may more accurately predict
mortality in paediatric trauma patients than scoring sys-
tems currently in use [42].
Measurements of admission base deficit are frequently
used as markers of tissue hypoperfusion and shock. The
prognostic value of lactate levels has not yet been defined
in paediatric patients. Several investigators suggest using
shock index (defined as heart rate/systolic blood pressure)
as an indicator of tissue perfusion as it reflects both vascu-
lar and myocardial dysfunction [43,44].
The presence of hypovolaemic shock in paediatric
trauma patients with coinciding coagulopathy corre-
lates well with data from adult trauma populations,
where drivers of trauma-induced coagulopathy include
acidosis as a result of hypovolaemic shock and con-
sumption of coagulation factors secondary to local acti-
vation of the coagulation system after severe traumatic
injury [34,45]. A distinct mechanism of trauma-induced
coagulopathy involving activation of the anticoagulant
protein C pathway, caused by tissue hypoperfusion
[41,45] has also been described, and recently high en-
dogenous catecholamine levels and endothelial damagehave also been proposed to promote coagulopathy in
trauma [46-48].
Massive transfusion protocols in paediatric trauma
patients
Quick instigation of a balanced transfusion strategy with
RBC, FFP and PLT in a 1:1:1 unit ratio combined with
early, repeated coagulation monitoring and goal-directed
transfusion therapy, are intricate parts of the HR concept
as described above [10-12]. A restrictive use of crystalloids
to decrease coagulopathy induced by haemodilution is also
emphasized [10,11]. The adverse effects of haemodilution
in children were described by Hussmann et al., who found
that increased prehospital crystalloid volume replacement
was associated with increased transfusion requirements,
adversely affected coagulation (defined by a prolonged PT)
and a tendency towards increased mortality and multi
organ failure (MOF) rates [49].
Resuscitation with appropriate volumes and blood
products is critical because both anaemia and hypovol-
emia decrease oxygen delivery to the tissues [21,25].
Besides containing fibrinogen, which is essential for clot
formation, FFP is an excellent volume expander. So is
RBC, and patients that require massive transfusion should
therefore be given RBC and FFP as volume therapy to
treat their hypovolemia causing hypoperfusion with ensu-
ing oxygen debt and coagulation factor depletion, rather
than crystalloids [16].
Studies in adult populations have shown that an in-
creased ratio of PLT and FFP to RBC show an association
with improved survival in massively bleeding trauma and
non-trauma patients [15,16,50,51]. Nosanov et al. did not
find the same association between increased FFP or PLT
to RBC ratios and decreased mortality in massively trans-
fused paediatric trauma patients [22]. This group defined
massive transfusion as more than 50% of total blood vol-
ume lost within 24 hours. However, this 24 hour based
definition of massive transfusion does not differentiate be-
tween patients with different bleeding dynamics in the
hours after the trauma (massive initial bleeding versus
later moderate, prolonged bleeding). Moreover, the study
population was small (105 patients), low and heterogenous
in their component ratios and all fatalities within the first
24 hours were excluded from the study, making the results
susceptible to indication bias.
Use of warm fresh whole blood used in combat set-
tings for adult patients with traumatic injuries have
shown to be independently associated with improved
30-day survival [52]. Manno et al. conducted a small
randomized controlled study of 161 children undergo-
ing open heart surgery with cardiopulmonary bypass,
meeting postoperative transfusion requirements with
either 24–48 hour old whole blood stored at 4 degrees
Celcius or reconstituted whole blood (RBC/FFP/PLT).
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blood loss in the group receiving fresh whole blood, and
ascribed this to better functioning platelets [53]. Recently,
refrigerated whole blood treated with pathogen reduction
technology maintained in vitro haemostatic function for at
least 10–14 days if stored appropriately at 4 degrees
Celcius [54]. Based on these data, whole blood could
potentially be used as an alternative to reconstituted whole
blood in trauma settings for haemostatic resuscitation, in
centres that are able to handle and store it correctly. More
investigation into the utility of whole blood in the emer-
gency setting for paediatric resuscitation is warranted.
At present, only two single-centre studies and few
case reports have documented their experiences with
the use of a predefined MTP in paediatric patients
(Table 1). Hendrickson et al. conducted a study comparing
the outcomes of 53 patients receiving a predefined MTP
with 49 historic controls. This MTP contained weight-
based blood product “packages” with fixed balanced ratios
of blood products. The intended ratio of FFP:RBC was 1:1,
and every other package also contained apheresis platelets
or cryoprecipitate units. Only 50 percent of the patients in
the MTP group required massive transfusion (defined as >
70 ml/kg total blood products transfused). Massively trans-
fused patients received twice the ratio of FFP:RBC as the
historic controls (1:1.8 compared to 1:3.6). The group did
not find a statistically significant reduction in mortality
(38% vs. 23%, p = 0.35) after MTP implementation when
taking injury severity and coagulopathy (Table 1) into
account in the multivariate analysis. Importantly, the
majority of patients in both the pre-MTP and MTP group
(80% vs. 72%) were found to have at least one abnormal
coagulation value at presentation to the ED [3].
Chidester et al. conducted a prospective study of 55
children, 22 of them received blood transfusions ac-
cording to a MTP and 33 patients were transfused at
physician discretion. Massive transfusion was at this
institution defined as ≥ 1 blood volume transfused
within 24 hours or half of a blood volume in 12 hours.Table 1 Studies evaluating the effect of a massive transfusion







Hendrickson et al. [3] 102
RC vs.
PI
1:1.8 vs. 1:3.6 1:6.7 vs. 1:5.9 38% v
Chidester et al. [20] 55 PI 1:3 vs. 1:3 NR
45% v
NR)
Dressler et al. [56] 1 Case 4:4 5:4 NA
Pickett et al. [57] 1 Case 3:6 5:6 NA
Paterson et al. [58] 1 Case 1:1.5 1:1.5 NA
1Abnormal coagulation parameters defined as prothrombin time (PT) >15.9 sec, partial th
2Early coagulopathy defined by a PTT > 36 seconds.
RC: retrospective cohort; PI: prospective intervention; Case: case report; FFP: fresh fr
NA: not applicable; MTP: massive transfusion protocol; ED: emergency department.Even though the total number of blood products
transfused was greater in the MTP group, the actual
blood product ratio between the groups showed no
statistically significant difference with a mean ratio
FFP:RBC of 1:3 in both groups. Early coagulopathy
(Table 1) was associated with MTP activation. No sig-
nificant difference in mortality was found between the
two groups (45% vs. 45%). However, they did find that
the patients in the MTP group had a significantly
higher ISS, and that 4 thromboembolic events oc-
curred in the non-MTP group versus 0 in the MTP
group, which the group attributed to under transfu-
sion of the non-MTP group (Table 1) [20].
Dressler et al. described the use of a MTP in the case
of a 9-year old boy with severe intraoperative bleeding
(>4 liters). They applied a blood product ratio of 4:4:5
units of RBC:FFP:PLT perioperatively and did not find
signs of coagulopathy postoperatively [55].
Pickett et al. described the use of a MTP consisting of
6:3:5 ratio of RBC:FFP:PLT for pre- and perioperative
transfusion in a 15-year old boy with an estimated blood
loss of 10 liters due to a gunshot wound to the chest.
The patient did not present with or develop coagulopa-
thy after resuscitation [56].
Paterson et al. presented the case of a 5-year old girl
with severe intracranial bleeding due to an arterio-
venous malformation, resulting in an estimated loss of
more than 5–6 blood volumes. Their MTP, after the loss
of 2 blood volumes with expected continued bleeding,
consisted of RBC, FFP and PLT given in a ratio of
30:20:20 ml/kg (total 70 ml/kg) in each cycle. The pa-
tient survived and was admitted to the ICU with a nor-
mal postoperative coagulation profile [57].
Pro-haemostatics in paediatric trauma patients
The use of adjuvant haemostatic agents has not been
systemically assessed in paediatric patients.
Thrombelastometry guided infusion of fibrinogen was




The majority of pre-MTP (80%) and MTP (72%)
patients had at least one abnormal coagulation
value on presentation to the ED1
s. 45% (p value Early coagulopathy2 initiated MTP. 4 thrombo-embolic
events in the non-MTP group vs. 0 in the MTP group
romboplastin time (PTT) >42.1 sec, fibrinogen <180 mg/dl or platelets < 185 × 109/l.
ozen plasma; RBC: red blood cells; PLT: platelet concentrate; NR: not reported;
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craniosynostosis as well as in a case report depicting a
child with severe abdominal and pelvic injuries following
blunt trauma [58,59].
The use of tranexamic acid in paediatric patients
undergoing cardiac surgery was evaluated in a systemic
review from 2012 including 8 studies (848 patients). Due
to heterogeneous data including marked variability in
dosage, the effects of tranexamic acid on postoperative
morbidity and mortality could not be evaluated. Nor
could potential side effects associated with the drug [60].
Recombinant factor VIIa (rFVIIa) has been a useful adju-
vant to blood component therapy in achieving haemostasis
in severely haemorrhaging neonatal and paediatric patients
who did not have haemophilia [61,62], and case reports
have described rapid correction of coagulopathy in head-
injured children with rFVIIa [63]. A retrospective study in-
cluding 135 children who had received rFVIIa for off-label
use, showed significantly decreased blood-product admin-
istration but also associated severe thromboembolic events
in children who had received rFVIIa [64].
Hence, more research is needed before these adjuvants
can be utilized beyond their restricted use and their role
in the treatment of bleeding paediatric trauma patients
can be established.
Colloid use in paediatric trauma patients
Haemodilution with large amounts of colloids may have
negative effects on haemostasis [65,66]. Comparing the
effects of hydroxyethyl starch (HES) and human albumin
(HA) on coagulation by thrombelastography in children
weighing 3–15 kg, Haas et al. found significantly more
impaired coagulation after the use of HES [66]. Volume
replacement with HA may be associated with increased
mortality in trauma patients with TBI when compared to
saline [67]. Caution is therefore warranted, and colloids
should not be used for volume replacement in the trauma
setting given the high incidence of early coagulopathy and
TBI in the paediatric trauma population [3,6,7].
Coagulation monitoring
Coagulopathy in trauma has historically been described
as multifactorial, attributed to acidemia and hypothermia
combined with dilution and consumption of clotting fac-
tors and platelets secondary to fluid administration and
bleeding [14]. An early acute traumatic coagulopathy in-
duced by trauma and hypoperfusion (shock) was re-
cently identified, as described above.
Early monitoring of coagulation is essential to identify
coagulopathy, and this is routinely based on conven-
tional plasma based coagulation tests such as PT, APTT,
INR, fibrinogen and platelet count [68]. These plasma-
based tests, however, only reflect the initiation of the
haemostatic process and poorly correlate with clinicallyrelevant coagulopathies [69,70]. Moreover, several of
them are imprecise in young children.
Viscoelastic haemostatic assays (VHA) such as Thrombe-
lastography (TEG®)/thromboelastometry (ROTEM®) analyse
the viscoelastic properties of whole blood, thereby reflecting
the entire haemostatic process allowing for a more qualita-
tive analysis of the individual cellular components and their
interactions in haemostasis [70,71]. Inherent limitations to
the interpretation of VHA results are, that the inhibitory ef-
fect of antithrombotic medications such as clopidogrel and
aspirin on platelet aggregation can only be assessed using
the TEG® Platelet Mapping assay. This assay has been used
perioperatively to evaluate the activation of arachidonic acid
and adenosine diphosphate pathways, specifically assessing
the potential inhibition of those pathways by aspirin and
clopidogrel [72,73].
The use of VHA in massively bleeding paediatric
patients have not yet been firmly established.
Vogel et al. recently found that rapid TEG (rTEG) on
admission was a useful real-time tool in assessing coagu-
lopathy and directing haemostatic resuscitation in paediat-
ric trauma patients. Furthermore, the admission rTEG
was predictive of early transfusion requirements and cor-
related with outcome [74]. These results are in alignment
with other investigators including our own group, where
TEG® has been shown to reflect acute coagulopathy of
trauma and predict morbidity and mortality in adult
trauma patients [75-77]. A further advantage of applying
TEG®/ROTEM® compared to standard plasma based tests
is that they provide faster results [33,75]. Importantly, age-
specific reference values exist for the use of TEG®/
ROTEM® in paediatric patients [32,78]. From data based
on 359 children aged 0 months to 16 years, an attempt to
establish age-dependent reference values for ROTEM® as-
says revealed that children aged 0–3 months, despite
showing prolonged standard plasma coagulation test re-
sults (prolonged PT and APTT), exhibited accelerated co-
agulation times compared to older children and adults,
and a strong clot firmness within the range of adults. Lysis
indices of < 85% were observed in nearly one third of all
children less than 16 years of age without increased bleed-
ing tendency [32]. Chan et. al did not find age-related dif-
ferences in kaolin-activated TEG variables, and attributed
this to the balanced maturational differences in coagula-
tion factor levels and coagulation inhibitors in children.
However, they did conclude that reference values depend
on the specific analyzers and activators used [78], since
significant differences in R and K times have been found
when using kaolin versus celite as an activator [79].
Early identification and implementation of goal-directed
treatment of traumatic coagulopathy could, potentially, im-
prove outcome in trauma patients. Therefore, the use of
VHA to assess coagulopathy and to guide blood transfusion
therapy has been recommended in the recent European
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trauma patients [68].
At our institution, both adult and paediatric patients with
uncontrolled bleeding are treated with predefined transfu-
sion packages, based on HR principles involving early ad-
ministration of FFP (pre-thawed plasma is always available
for immediate delivery) and PLT (whole blood derived
platelet concentrate) [80]. The transfusion package encom-
passes five units of RBC, five units of FFP and two units of
platelet concentrates for adults whereas for children, the
recommended ratio is 20:20:10 ml/kg of RBC:FFP:PLT
(Figure 1). Based on the results of real-time TEG® analyses,
goal-directed treatment with specific blood products and
pro-coagulant adjuvants (tranexamic acid, cryoprecipitate,
fibrinogen) are administered according to protocol and ex-
pert opinion, basing interventions primarily on the clinical
presentation of the patient together with the real time
TEG® results. The implementation of this MTP has led to
increased survival of massively bleeding adult patients at
our institution [15,80], but results from paediatric data are
still pending.
Romlin et al. found that the routine use of intraoperative
ROTEM® in paediatric cardiac surgery to guide transfusions
was associated with a reduced number of patients receiving
transfusions, and that fewer patients in the study group re-
ceived RBC and FFP, whereas more were transfused with
platelet and fibrinogen concentrates [81]. A reduction in
bleeding and in the number of patients requiring transfu-
sion of FFP and PLT with VHA monitoring was confirmed
by a meta-analysis on adult patients from the Cochrane in-
stitute [82]. The ability of VHA guided HR to reduce the
total number of blood products transfused is an important
attribute, considering the possible adverse effects associated
with transfusion therapy in critically ill children.
Risks associated with blood product transfusion in children
Safety issues relating to the transfusion of blood prod-
ucts include infectious and non-infectious risks.Clinical signs Stable Tachycardia* 
Blood loss 0-10 ml/kg 10-20 ml/kg 2
Crystalloid ** 10 ml/kg 0 
RBC 0 10 ml/kg 
FFP *** 0 10 ml/kg 
Platelet concentrate 0 0 
TEG®/ROTEM® + + 
Cryoprecipitate, Fibrinogen, Tranexamic Acid etc. used goal-
monitoring 
Figure 1 Massive transfusion protocol for paediatric trauma patients
blood cells; FFP: fresh frozen plasma. * Or narrowed pulse pressure or othe
*** Thawed FFP is available ensuring early use.Transmission of infectious diseases are extremely rare,
but children have a higher incidence of adverse reac-
tions to transfusion of blood products than adults - and
more than 80% of these are estimated to be caused by
human errors [83]. Febrile non-haemolytic transfusion
reaction is the most common reaction encountered,
whereas acute haemolytic transfusion reactions due to
AB0 incompatibility account for the vast majority of
transfusion-related deaths [21]. Moreover, transfusion of
blood products can cause volume overload, electrolyte dis-
turbances often with hypocalcemia and hyperkalemia as
well as dilutional coagulopathy [21].
Pieracci et al. did a retrospective pilot study of 43 paediat-
ric trauma patients. This group found that early RBC trans-
fusion (<6 hours from admission) was associated with
increased mortality, and that late RBC transfusion (≥6 hours
from admission) was associated with an increased length of
stay in the ICU and more ventilator days compared to non-
transfused patients [84]. However, only 30% of the early fa-
talities were due to exsanguination, central nervous system
injury was the main cause of death. Similarly, Stone et al.
identified an association between transfusion of RBC within
the first 24 hours after admission and increased mortality,
prolonged duration of mechanical ventilation and ICU ad-
mission in a larger retrospective study of paediatric trauma
patients [85]. However, shock index and ISS were all signifi-
cantly higher in the transfused group. Since both these
studies were based on retrospective data, the results are
likely to be influenced by indication bias given the differ-
ences in demographics of the groups being compared. A
dose-dependent relationship between the number of RBC
transfusions and mortality was observed by Kneyber et al.
in critically ill paediatric ICU patients but interestingly, no
correlation was found between the pre-transfusion haemo-
globin concentration and mortality [86].
Like that observed for RBC, plasma transfusions have
also been found to be independently associated with an
increased occurrence of new or progressive MOF,Ongoing 
bleeding
Haemodynamic instability 
0-40 ml/kg 1 BV lost 2 BV lost 
For every BV 
lost 
0 0 0 0 
20 ml/kg 20 ml/kg 20 ml/kg 20 ml/kg 
20 ml/kg 20 ml/kg 20 ml/kg 20 ml/kg 
10 ml/kg 10 ml/kg 10 ml/kg 10 ml/kg 
+ + + + 
directed according to concurrent TEG®/ROTEM® 
in Copenhagen, Denmark. BV: estimated blood volume; RBC: red
r signs of hypovolemia: ** No use of colloids (synthetic or natural):
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critically ill children [87].
The results outlined above are all from descriptive, retro-
spective studies. This entails the risk of confounding by in-
dication and no cause-effect relationship between blood
product transfusion and increased morbidity or mortality
can be firmly established using the results of these descrip-
tive studies. In the TRIPICU trial, there was no change in
mortality when being restrictive with RBC and only an in-
significant reduction of nosocomiel infections from 25 to
20% in the restrictive group [28]. Transfusion of RBC
stored for more than 14 days has, however, shown an asso-
ciation with increased incidence of multiple organ dysfunc-
tion and longer intensive care unit stays in critically ill
children [88,89].
Considering the outlined possible risks of blood product
administration, it should be noted that Cotton et al. found
that implementing a predefined MTP actually reduced the
incidence of MOF, infectious complications and the num-
ber of ventilator days in severely injured adult trauma pa-
tients [9]. Patients transfused according to the MTP also
had reduced mortality. Though receiving more blood
products intraoperatively, patients who were transfused
according to the MTP had lower total transfusion require-
ments within the first 24 hours compared to controls [17],
and this result is in alignment with Johansson et al. [90].
These findings support the hypothesis that early and ag-
gressive administration of FFP and PLT can improve
haemostasis, reduce bleeding and subsequently improve
outcome.
Conclusions
Haemorrhage is a leading cause of death in paediatric
trauma patients. Predefined MTP have the potential to sig-
nificantly reduce mortality by treating haemorrhagic shock
and coagulopathy, thereby ensuring adequate oxygen deliv-
ery and haemostasis in massively bleeding paediatric trauma
patients, especially considering the high prevalence of early
coagulopathy in this population. The triggers for MTP acti-
vation in paediatric trauma patients and the optimal blood
product ratio that will increase survival in massively bleed-
ing paediatric trauma patients still have to be determined.
Despite not yet having been tested in paediatric populations,
MTP with increased PLT to FFP to RBC ratios combined
with VHA guided component therapy seem promising,
based on results in adult patients. Prospective randomized
trials investigating this therapeutic approach in paediat-
ric trauma populations are highly warranted.
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